Aigen Investment Management LP Invests $216,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Aigen Investment Management LP purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,515 shares of the company’s stock, valued at approximately $216,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SPRY. Compass Capital Corp MA ADV purchased a new stake in shares of ARS Pharmaceuticals during the 4th quarter worth $106,000. Quarry LP acquired a new position in ARS Pharmaceuticals during the third quarter worth about $174,000. Stifel Financial Corp acquired a new position in ARS Pharmaceuticals during the third quarter worth about $199,000. Intech Investment Management LLC purchased a new position in ARS Pharmaceuticals in the third quarter valued at about $239,000. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at approximately $175,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, COO Brian Dorsey sold 25,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $12.30, for a total value of $307,500.00. Following the completion of the transaction, the chief operating officer now directly owns 6,024 shares in the company, valued at approximately $74,095.20. The trade was a 80.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sarina Tanimoto sold 100,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total value of $1,316,000.00. Following the transaction, the insider now directly owns 1,148,499 shares in the company, valued at approximately $15,114,246.84. This represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 401,872 shares of company stock valued at $4,845,916 in the last ninety days. Insiders own 40.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SPRY. Oppenheimer initiated coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price target on the stock. Raymond James upped their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Scotiabank assumed coverage on ARS Pharmaceuticals in a research note on Friday. They set a “sector outperform” rating and a $30.00 price target for the company. Leerink Partners boosted their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Finally, William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ARS Pharmaceuticals presently has an average rating of “Buy” and an average target price of $29.00.

ARS Pharmaceuticals Stock Up 0.6 %

SPRY opened at $10.85 on Monday. The firm has a market cap of $1.05 billion, a P/E ratio of -21.27 and a beta of 1.03. The business’s fifty day simple moving average is $11.87 and its 200 day simple moving average is $13.12. ARS Pharmaceuticals, Inc. has a 52 week low of $7.55 and a 52 week high of $18.51.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.